160 related articles for article (PubMed ID: 29254882)
1. The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis.
Vizza CD; Badagliacca R; Messick CR; Rao Y; Nelsen AC; Benza RL
Int J Cardiol; 2018 Mar; 254():299-301. PubMed ID: 29254882
[TBL] [Abstract][Full Text] [Related]
2. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
[TBL] [Abstract][Full Text] [Related]
3. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
Gaine S; Simonneau G
Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
[TBL] [Abstract][Full Text] [Related]
4. Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis.
Faisal M; Siddiqi F; Alkaddour A; Bajwa AA; Shujaat A
Pulm Med; 2014; 2014():528783. PubMed ID: 25478223
[TBL] [Abstract][Full Text] [Related]
5. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
Farber HW; Miller DP; McGoon MD; Frost AE; Benton WW; Benza RL
J Heart Lung Transplant; 2015 Mar; 34(3):362-8. PubMed ID: 25312386
[TBL] [Abstract][Full Text] [Related]
6. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.
Neal JE; Lee AS; Burger CD
Clin Respir J; 2014 Oct; 8(4):404-9. PubMed ID: 24308300
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
He CJ; Chen SJ; Wang J; Zhu CY; Yin YH
Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006
[TBL] [Abstract][Full Text] [Related]
8. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.
Huang J; Mehta S; Mura M
Respiration; 2015; 89(5):365-73. PubMed ID: 25791910
[TBL] [Abstract][Full Text] [Related]
9. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
Duo-Ji MM; Long ZW
Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
[TBL] [Abstract][Full Text] [Related]
11. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.
Gerhardt F; Dumitrescu D; Gärtner C; Beccard R; Viethen T; Kramer T; Baldus S; Hellmich M; Schönau E; Rosenkranz S
Heart; 2017 Apr; 103(8):592-598. PubMed ID: 28100544
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
13. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
14. Six-minute walk test in pulmonary arterial hypertension.
Demir R; Küçükoğlu MS
Anatol J Cardiol; 2015 Mar; 15(3):249-54. PubMed ID: 25880178
[TBL] [Abstract][Full Text] [Related]
15. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension.
Provencher S; Chemla D; Hervé P; Sitbon O; Humbert M; Simonneau G
Eur Respir J; 2006 Jan; 27(1):114-20. PubMed ID: 16387943
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
Studer SM; Gilkin RJ
Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
[TBL] [Abstract][Full Text] [Related]
17. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis.
Modrykamien AM; Gudavalli R; McCarthy K; Parambil J
Respir Care; 2010 May; 55(5):584-8. PubMed ID: 20420729
[TBL] [Abstract][Full Text] [Related]
18. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA
J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961
[TBL] [Abstract][Full Text] [Related]
19. Treatment goals of pulmonary hypertension.
McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
[TBL] [Abstract][Full Text] [Related]
20. Six-minute walk distance target in elderly patients with idiopathic pulmonary arterial hypertension - consideration of predicted values.
Lange TJ; Keller A; Arzt M; Pfeifer M
Int J Clin Pract; 2014 May; 68(5):543-50. PubMed ID: 24472027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
